AFIB
Acutus Medical Inc
Acutus Medical Inc
$AFIB Reports Strong Q1 2023 Results with Improved Gross Margin, Reduced Operating Expenses, and Increased Revenue
Acutus Medical has reported strong Q1 2023 financial results, showing YoY improvements in non-GAAP gross margin, operating expenses, and cash burn. The firm generated $22.4m in revenue, up from $13.7m YoY, with a net loss of $16m. Acutus Medical's actions in the first half of 2022, such as restructuring and spending reductions, have contributed to positive results. With $76.7m in cash and cash equivalents, the company's financial position is strong. These results may be appealing to investors searching for growth opportunities in arrhythmia management. However, Acutus Medical uses non-GAAP financial measures.
4mo ago
$AFIBAcutus Medical Inc
$AFIB reports robust Q4 revenue growth and improved financials
Acutus Medical's Q4 and FY2022 unaudited financial results revealed increased revenue of $33.4M, up from $19.4M in the same period in 2021, due to demand for differentiated mapping and therapy platforms and geographic expansion. With a gross margin of 75%, the company aims to continue to improve it in 2023, while a net loss of $39.1M for 2022 narrowed from $107.3M in 2021. Acutus plans to sustain growth in 2023 through geographic expansion and driving adoption of the mapping and therapy platform. However, forward-looking statements are fraught with uncertainties, and investors should exercise caution when interpreting them.
6mo ago
$AFIB